Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00926380 · ClinicalTrials.gov registry record · Phase 2
Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT00926380: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00926380 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 94 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00926380, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
The aim of this study is to determine whether denosumab (an FDA-approved osteoporosis therapy), in combination with teriparatide (an FDA-approved osteoporosis therapy), will increase bone mineral density more than either one alone in postmenopausal osteoporotic women.
Interventions
- DRUG denosumab
- DRUG teriparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2009-06 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00926380
The ClinicalTrials.gov registry entry for NCT00926380 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which denosumab is the first listed.
NCT00926380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00926380 about?
NCT00926380 is a clinical study titled "Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis". The aim of this study is to determine whether denosumab (an FDA-approved osteoporosis therapy), in combination with teriparatide (an FDA-approved osteoporosis therapy), will increase bone mineral density more than either one alone in postmenopausal osteoporotic women.
What is the current status of trial NCT00926380?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2009-06. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00926380?
The interventions under investigation include: denosumab (DRUG), teriparatide (DRUG).
Who is sponsoring clinical trial NCT00926380?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.